Hemispherx Biopharma Retains Anderson Clinical Research to Initiate Phase 2/3 Trials in HIV Disease
PHILADELPHIA, Jun 20, 2000 /PRNewswire via COMTEX/ -- Hemispherx Biopharma,
Inc. (Amex: HEB; HEBws) said it has retained the services of Anderson Clinical
Research, Inc. ("Anderson") with respect to design and implementation of its
Phase 2/3 trials in HIV disease. Anderson is one of the leading Clinical
Research Organizations (CRO) specializing in innovative HIV research.
Anderson Clinical Research, Inc., which is based in Pittsburgh, PA, is
world-recognized for conducting expedited clinical trials in AIDS which
thereafter become the basis for full drug marketing authorizations. Anderson has
operated AIDS-related clinical trials for most of the multinational
pharmaceutical companies involved in advanced AIDS treatments. Eight major
metropolitan locations in the U.S., plus four treatment sites in New York City,
are utilized as core referral centers. Anderson has conducted many successful
Phase 2, 3 and 4 (post-marketing approval) clinical programs on the panel of
fourteen antivirals which are the present foundation for AIDS treatment.
"We are very excited about the prospects for Ampligen(R) to fill a major void in
our overall therapeutic approach to HIV," said Roger Anderson, M.D., Chief
Executive Officer and President of Anderson Clinical Research, Inc.
Hemispherx said that the new clinical rationale and new ex vivo data, underlying
the new treatment program, would be presented by the Medical Directors of
Anderson at the upcoming July, 2000, International AIDS Conference in Durban,
South Africa. The AIDS conference organizers expect attendance in the thousands
by researchers, physicians, advocacy groups and media science writers, each
representing various parts of the world affected by the global epidemic.
Information contained in this news release other than historical information,
should be considered forward-looking and is subject to various risk factors and
uncertainties. For instance, the strategies and operations of Hemispherx involve
risks of competition, changing market conditions, changes in laws and
regulations affecting these industries and numerous other factors discussed in
this release and in the Company's filings with the Securities and Exchange
Commission. Accordingly, actual results may differ materially from those in any
forward-looking statements.
SOURCE Hemispherx Biopharma, Inc.
CONTACT: William A. Carter, M.D., CEO & Chairman, 215-988-0080, or
Dianne Will, Investor Relations, 214-954-9300, fax, 214-954-9333, both of
Hemispherx Biopharma; or Mark Kollar, Institutional Investors of Broadgate,
212-232-2222, fax, 212-232-3232, for Hemispherx; or Roger Anderson, M.D. of
Anderson Clinical Research, 412-247-2285
URL: hemispherx.com |
